Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

GSK CONSUMER Fact Sheet, GSK CONSUMER Financial Results - Equitymaster

Jan 29, 2022 | Updated on Jan 29, 2022

Check out GSK CONSUMER fact sheet and GSK CONSUMER financial results online at Equitymaster.

GSK CONSUMER Quarterly Results - Equitymaster

Apr 15, 2020 | Updated on Apr 15, 2020

Check out latest GSK CONSUMER Quarterly Results online at Equitymaster.

GSK CONSUMER Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Apr 15, 2020 | Updated on Apr 15, 2020

GSK CONSUMER: Get the latest GSK CONSUMER Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

SBCH: Blockbuster June quarter

Jul 25, 2003

GlaxoSmithkline Consumer Healthcare (SBCH) has posted a strong 27% topline growth during the June quarter. It seems that the company's relaunch strategy for both Horlicks and Boost seems to have rubbed off on the performance. It may also be an indication that the inventory correction undertaken by the company last year is now over. There is a minor difference between our revenue growth and the reported growth due to change in numbers of previous quarter figures.

GSK Consumer: Bad news continues

Apr 16, 2003

GlaxoSmithkline Consumer Healthcare Ltd. (SBCH) has posted a 38% dip in its 1QFY04 net profits. Though we do not have the company's detailed release on the results, as per the declared numbers, the company's gross sales has dipped by over 4% during the March quarter. The company has however, clarified that it has not lost market share in the malted beverage segment. With this, SBCH's poor showing continues.

SBCH: Improvement signs…

Oct 25, 2002

GlaxoSmithKline Consumer Healthcare Ltd. (erstwhile SmithKline Beecham Consumer Healthcare) has posted a much better performance in September quarter, as compared to the June quarter. The malted beverage major reported a 4% growth in topline and finished the quarter with 15% dip in bottomline.

SBCH: Opportunity in adversity

Sep 24, 2002

Malted beverage major, GlaxoSmithKline Consumer Healthcare (SBCH), has seen its stock price crash to new lows. The counter has seen an over 30% decline in the last 5 months. The pessimism has come about ever since the company declared a huge 26% drop in June quarter topline and 45% decline in bottomline.

SBCH: Malt king weakening?

Aug 2, 2002

GlaxoSmithKline Consumer Healthcare Ltd. (erstwhile SmithKline Beecham Consumer Healthcare) posted diappointing results for the June quarter. The company posted a never before 26% decline in the topline in 1QFY03. This resulted in the margins getting squeezed and the company finally finished the quarter with a significant 45% dip in bottomline.

SBCH: Feels the heat

Apr 22, 2002

FMCG sector continues to feel the heat of an economic slowdown. This is reflected in the slowing revenue growth of SmithKline Beecham Consumer Healthcare (SBCH). The company's turnover in the March quarter hardly saw any growth, compared to a 13.5% rise recorded in FY02. Although, it managed to improve operating margins, deferred taxes pressurized earnings.

SBCH: Competitive pressure

Feb 6, 2002

FMCG sector continues to feel the heat of an economic slowdown. This is reflected in the slowing revenue growth of SmithKline Beecham Consumer Healthcare (SBCH). The company's turnover in the December quarter rose in single digits compared to a 21% rise recorded in 1HFY02. Although, it managed to improve operating margins, higher interest burden pressurized earnings.

Growing on malted strengths

Jan 5, 2002

SmithKline Beecham Consumer Healthcare (SBCH) dominates the Rs 13 bn Indian malted beverage market with over 65% share. Its brand ‘Horlicks’ has led to growth of this sector in India. The company’s other brands include ‘Boost’, ‘Viva’ and ‘Maltova’. SBCH has a strong marketing and distribution network in India comprising over 1,600 wholesalers and direct coverage of over 400,000 retail outlets.

SBCH: Slowdown catches up

Oct 19, 2001

Smithkline Beecham Consumer Healthcare Limited (SBCH) has posted a 7% decline in 3QFY02 net profit to Rs 283 m. If we exclude the extraordinary expense burden from last year's numbers then the profit has fallen by 13%. The decline in profits was primarily as a result of expenditure increasing at a faster clip than sales as well as increased taxation provisioning on account of deffered taxes. The tax burden went up by 64% YoY during the quarter. The company's sales (including excise) went up by o

SBCH: A take on valuations

Sep 27, 2001

About a fortnight ago, we had written a story on the sliding growth signals from SmithKline Beecham Consumer Healthcare (SBCH). A lot has changed since then. The uncertainty in the global economy post the attacks on the WTC have seen the Indian bourses slide by nearly 20% and valuations of all sectors have plunged. Even SBCH stock has declined by 11% in the last fortnight. Under these circumstances we revisit the company’s prospects and valuations.

SBCH: Concerns surface

Sep 11, 2001

SmithKline Beecham Consumer Healthcare (SBCH) is one of the few FMCG companies that had remained insulated from the economic downturn. Infact, in the first six months of FY02 (January-June 2001) sales growth was a significant 21% and bottomline growth was nearly 37%. However, data appearing in the news articles suggests that the company’s sales growth has been marginally negative for the month of July.

SBCH: Malt powered performance

Jul 27, 2001

Malted beverage major, SmithKline Beecham Consumer Healthcare (SBCH), has posted impressive growth in the second quarter. In 2QFY02, the company has declared a 45% growth in bottomline. What is even more interesting is that its topline has shown a growth of 17.5%.

SBCH: Will Iodex break jinx?

Jun 26, 2001

There is news that Glaxo Smithkline Beecham Pharmaceuticals is transferring its Rs 750 m brand, Iodex, to Smithkline Beecham Consumer Healthcare Limited (SBCH). Iodex, the leader in pain balms, is predominantly an over the counter (OTC) product, with more than 90% of sales from this route. The rest is sold through chemist shops. However, the consideration or the royalty on sales to be paid to Glaxo SmithKline is yet to be decided.

SBCH turnover jumps 25%

Apr 20, 2001

SmithKline Beecham Consumer Healthcare (SBCH) has declared a 26% jump in its 1QFY02 bottomline YoY. The company not only continues to show strong growth in its net profits, its topline too has grown by nearly 25% YoY.

SBCH: Time for re-rating?

Feb 16, 2001

In these days of old economy boom, FMCG companies too have gained considerable ground. But the same does not hold true for malted beverages major, Smithkline Beecham Consumer Healthcare (SBCH). Let's take a look.

SBCH: 22% topline growth in FY01

Feb 2, 2001

Malted beverages major, Smithkline Beecham Consumer Healthcare Limited (SBCH), has posted a net profit of Rs 317 m in its fourth quarter ended December 31, 2000. This is only 5% up as compared to a net profit of Rs 301 m in the quarter ended December 31, 1999.

SBCH: Uninterrupted growth but…

Nov 29, 2000

SmithKline Beecham Consumer Healthcare (SBCH) has reported satisfactory financial growth over the last three years. After the acquisition of Maltova and Viva, the company became the leader in the health food drink market. It enjoys a market share of over 70% with its leading brands Horlicks and Boost.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS